(Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's ( PFE ) sickle cell disease drug Oxbryta on Thursday.

EMA said new data raise serious concerns about the safety of Oxbryta and added that the authorization, marketing and supply of the medicine be suspended until all the available data have been assessed in the ongoing review.

Late on Wednesday, Pfizer ( PFE ) said it was withdrawing Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.